ClinicalTrials.gg

Program

RO7568282

A development code.

Its studies are mostly in Parkinson Disease · Alzheimer Disease, led by Hoffmann-La Roche.

Furthest: phase 2, since Aug 20, 20262 company-led studies, 2 open or runningNext primary completion: Dec 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche22 open or runningphase 2since Aug 20, 2026Aug 20, 2026Dec 15, 2028phase 2 · NCT07781644

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2026First studies: 2 phase 2 studiesFirst studyNCT07781657, NCT07781644

Ahead

  1. Dec 15, 2028Primary completion: phase 2 study in Parkinson DiseaseNCT07781644
  2. Nov 1, 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07781657

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07781657Alzheimer Disease · United States, Australia, France and more2RecruitingNov 1, 2029450
NCT07781644Parkinson Disease · United States, China, Ireland and more2RecruitingDec 15, 2028474

How it is read

Names in the registry

  • “RO7568282”, 2 entries

Codes read as this program: RO7568282.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.